Want to see ANTX full AI Analyst Report?

AN2 Therapeutics, Inc. (ANTX) Price & Analysis

106 Followers

ANTX Stock Chart & Stats

$1.14

-$0.05(-3.70%)

At close: Jan 08 4:00 PM EST

$1.14

-$0.05(-3.70%)

Day’s Range― - ―

52-Week Range$1.00 - $6.91

Previous CloseN/A

Volume42.38K

Average Volume (3M)73.31K

Market Cap

$169.28M

Enterprise Value$80.78M

Total Cash (Recent Filing)$85.29M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta-0.07

Next Earnings

Aug 06, 2026

EPS Estimate

-0.23

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.10

Shares Outstanding36,016,163

10 Day Avg. Volume45,687

30 Day Avg. Volume73,314

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)0.65

Price to Sales (P/S)0.00

P/FCF Ratio-1.15

Enterprise Value/Market Cap0.48

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-2.25

Forecast

1Y Price Target

$9.00

Price Target Upside689.47% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.96

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

FundingCash, cash equivalents, and investments totaled $78.5M, anticipated to fund operations into 2028.

PartnershipsNow partnered with the Drugs for Neglected Diseases initiative (DNDi), AN2 can leverage DNDi’s extensive clinical trial network and expertise in Chagas disease to rapidly advance the Phase 2 planning for AN2-502998.

Regulatory OutlookThe FDA is likely to accept Quality of Life measures as an efficacy endpoint, which is beneficial for the drug's approval process.

Bears Say

Clinical TrialsThe final shoe has dropped for AN2 Therapeutics' epetraborole program in refractory MAC lung disease, as the EBO-301 Ph.3 study missed the primary endpoint.

Efficacy ResultsThe culture conversion results for epetraborole were disappointing, although not unexpected.

Study OutcomesUnfortunately, the truncated EBO-301 Ph.3 study missed the primary endpoint and was unable to confirm the clinical efficacy observed in the Ph.2 portion.

AN2 Therapeutics, Inc. News

AN2 Therapeutics reports data from two studies of AN2-502998 in Chagas disease

AN2 Therapeutics (ANTX) announced results from two studies evaluating the Company’s oral CPSF3 inhibitor, AN2-502998, for the treatment...

29d ago

ANTX

AN2 Therapeutics Holds 2026 Annual Stockholder Meeting

AN2 Therapeutics, Inc. ( ($ANTX) ) has provided an announcement. On June 3, 2026, AN2 Therapeutics, Inc. held...

24d ago

ANTX

AN2 Therapeutics Advances Chagas Candidate After Positive Trials

AN2 Therapeutics, Inc. ( ($ANTX) ) has shared an announcement. On June 4, 2026, AN2 Therapeutics reported positive...

28d ago

ANTX

AN2 Therapeutics upgraded to Outperform from Market Perform at Leerink

Leerink analyst Joseph Schwartz upgraded AN2 Therapeutics (ANTX) to Outperform from Market Perform with a $9 price target...

2M ago

ANTX

AN2 Therapeutics reports Q1 EPS (29c), one estimate (23c)

The Company had cash, cash equivalents and investments of $85.3 million at March 31, 2026. In March 2026,...

2M ago

ANTX

AN2 Therapeutics, Inc. (ANTX) Q1 Earnings Cheat Sheet

AN2 Therapeutics, Inc. (ANTX) is scheduled to report 1st quarter earnings on 05/13/2026. Regarding Q1 estimates, Wall Street...

2M ago

ANTX

AN2 Therapeutics Completes First-in-Human Trial, Setting Up the Next Catalyst for ANTX

AN2 Therapeutics, Inc. ($ANTX) announced an update on their ongoing clinical study. The Phase 1 trial “A Phase...

2M ago

ANTX

AN2 Therapeutics Launches New $80 Million ATM Program

An announcement from AN2 Therapeutics, Inc. ( ($ANTX) ) is now available. On April 9, 2026, AN2 Therapeutics...

3M ago

ANTX

AN2 Therapeutics files $300M mixed securities shelf

17:22 EDT AN2 Therapeutics (ANTX) files $300M mixed securities shelf Published first on TheFly – the ultimate source...

3M ago

ANTX

AN2 Therapeutics announces initiation of Phase 2 trial of epetraborole

AN2 Therapeutics (ANTX) announced the initiation of a Phase 2 investigator-initiated clinical trial evaluating the safety, efficacy, and...

3M ago

ANTX

AN2 Therapeutics Reprices Stock Options to Enhance Retention

AN2 Therapeutics, Inc. ( ($ANTX) ) has issued an update. On March 19, 2026, AN2 Therapeutics’ board approved...

3M ago

ANTX

AN2 Therapeutics reports Q4 EPS (29c) vs (25c) last year

“Our recent decision to advance oral epetraborole into a Phase 2 study for polycythemia vera highlights the growing...

4M ago

ANTX

AN2 Therapeutics Announces $40 Million Private Placement Financing

AN2 Therapeutics, Inc. ( ($ANTX) ) has shared an update. On March 8, 2026, AN2 Therapeutics entered into...

4M ago

ANTX

AN2 Therapeutics to advance oral Epetraborole into Phase 2 study

AN2 Therapeutics (ANTX) “announced its plans to expand the development of oral epetraborole into a Phase 2 proof-of-concept...

4M ago

ANTX

ANTX FAQ

What was AN2 Therapeutics, Inc.’s price range in the past 12 months?

AN2 Therapeutics, Inc. lowest stock price was $1.00 and its highest was $6.91 in the past 12 months.

What is AN2 Therapeutics, Inc.’s market cap?

AN2 Therapeutics, Inc.’s market cap is $169.28M.

When is AN2 Therapeutics, Inc.’s upcoming earnings report date?

AN2 Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 34 days.

How were AN2 Therapeutics, Inc.’s earnings last quarter?

AN2 Therapeutics, Inc. released its earnings results on May 11, 2026. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.23 by -$0.06.

Is AN2 Therapeutics, Inc. overvalued?

According to Wall Street analysts AN2 Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does AN2 Therapeutics, Inc. pay dividends?

AN2 Therapeutics, Inc. pays a Quarterly dividend of $0.656 which represents an annual dividend yield of N/A. See more information on AN2 Therapeutics, Inc. dividends here

What is AN2 Therapeutics, Inc.’s EPS estimate?

AN2 Therapeutics, Inc.’s EPS estimate is -0.23.

How many shares outstanding does AN2 Therapeutics, Inc. have?

AN2 Therapeutics, Inc. has 36,016,163 shares outstanding.

What happened to AN2 Therapeutics, Inc.’s price movement after its last earnings report?

AN2 Therapeutics, Inc. reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.23. Following the earnings report the stock price went down -9.534%.

Which hedge fund is a major shareholder of AN2 Therapeutics, Inc.?

Currently, no hedge funds are holding shares in ANTX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

AN2 Therapeutics, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-52.35%

Trailing 12-Months

Asset Growth

7.56%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.

AN2 Therapeutics, Inc. (ANTX) Earnings & Revenues

Historic Earnings Reports

ANTX Stock 12 Month Forecast

Average Price Target

$9.00

▲(689.47% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","5":"$5","10":"$10","2.5":"$2.5","7.5":"$7.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.5,5,7.5,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.7,5.030769230769231,5.361538461538462,5.6923076923076925,6.023076923076923,6.353846153846154,6.684615384615385,7.015384615384615,7.346153846153847,7.676923076923077,8.007692307692308,8.338461538461539,8.669230769230769,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.7,5.030769230769231,5.361538461538462,5.6923076923076925,6.023076923076923,6.353846153846154,6.684615384615385,7.015384615384615,7.346153846153847,7.676923076923077,8.007692307692308,8.338461538461539,8.669230769230769,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.7,5.030769230769231,5.361538461538462,5.6923076923076925,6.023076923076923,6.353846153846154,6.684615384615385,7.015384615384615,7.346153846153847,7.676923076923077,8.007692307692308,8.338461538461539,8.669230769230769,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.05,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.14,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.45,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.68,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.21,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.7,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >